| human | Q5 |
| P1280 | CONOR.SI ID | 185768803 |
| P2798 | Loop ID | 157604 |
| P496 | ORCID iD | 0000-0003-0566-4036 |
| P7293 | PLWABN ID | 9810602900105606 |
| P214 | VIAF ID | 313518810 |
| P69 | educated at | University of Innsbruck | Q875788 |
| P108 | employer | Tirol Kliniken | Q15851015 |
| P734 | family name | Decristoforo | Q37054002 |
| Decristoforo | Q37054002 | ||
| Decristoforo | Q37054002 | ||
| P735 | given name | Clemens | Q18180166 |
| Clemens | Q18180166 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q53505313 | (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? |
| Q53068468 | (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. |
| Q53046923 | (68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. |
| Q45399826 | 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression |
| Q53125755 | 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. |
| Q57757715 | 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT |
| Q43290075 | 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy |
| Q48295687 | 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour |
| Q57757849 | 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution |
| Q44661143 | 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. |
| Q48570816 | 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: methodological considerations |
| Q57757828 | 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives |
| Q51840066 | 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. |
| Q57757833 | 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide |
| Q47806075 | 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. |
| Q40533491 | 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. |
| Q57757710 | 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours |
| Q50902061 | A fully automated synthesis for the preparation of 68Ga-labelled peptides. |
| Q90273231 | A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study |
| Q53094166 | A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. |
| Q57757904 | A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine |
| Q44431022 | An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors |
| Q35551518 | An iron-mimicking, Trojan horse-entering fungi--has the time come for molecular imaging of fungal infections? |
| Q44794920 | Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. |
| Q57757517 | Are we "preparing" radiopharmaceuticals? |
| Q33484071 | Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. |
| Q48773045 | Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease |
| Q64230471 | Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m |
| Q91448177 | Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples |
| Q57757597 | Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours |
| Q91072082 | Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold |
| Q37230541 | Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors |
| Q93124250 | Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study |
| Q57757464 | Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy |
| Q33884461 | Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. |
| Q46684356 | Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotide. |
| Q53783567 | Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores. |
| Q92756458 | Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13 |
| Q47241139 | Current status of theranostics in prostate cancer. |
| Q45932863 | Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. |
| Q47158578 | Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression |
| Q90366016 | DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use |
| Q51753914 | Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting. |
| Q57757457 | Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors-An Improvement for Breast Cancer Imaging? |
| Q57757823 | Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phel-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide |
| Q57757859 | Determination of Sn(II) in technetium cold kits by voltammetry at the hanging mercury drop electrode (HMDE) and relevant radiopharmaceutical applications |
| Q33827092 | Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding |
| Q57757547 | EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) |
| Q89689509 | EANM guideline on the validation of analytical methods for radiopharmaceuticals |
| Q48316900 | Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. |
| Q48189196 | Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions |
| Q48152224 | Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. |
| Q92324162 | Erratum: Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum |
| Q28215919 | Erythroid 5-aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-dependent regulation |
| Q53546652 | European regulations for the introduction of novel radiopharmaceuticals in the clinical setting. |
| Q45225434 | Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. |
| Q44249031 | Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. |
| Q54579737 | Evidence for Somatostatin receptor 2 in thyroid tissue. |
| Q55263067 | Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression. |
| Q57757568 | Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies |
| Q57757892 | Failure of labelling of anti-granulocyte antibody |
| Q37990396 | Feasibility and availability of ⁶⁸Ga-labelled peptides. |
| Q36755148 | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
| Q43244229 | Full automation of (68)Ga labelling of DOTA-peptides including cation exchange prepurification. |
| Q51510849 | Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. |
| Q53180848 | Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification. |
| Q43125421 | Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68. |
| Q57757608 | Gallium-68 -- a new opportunity for PET available from a long shelf-life generator - automation and applications |
| Q33788353 | Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals |
| Q57757557 | Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective |
| Q48089118 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. |
| Q91823685 | Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals-Is This Possible? |
| Q26745705 | Highlights lecture EANM 2015: the search for nuclear medicine's superheroes |
| Q56336017 | Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can - make nuclear medicine great again" |
| Q94542881 | Hybrid Imaging Agents for Pretargeting Applications Based on Fusarinine C-Proof of Concept |
| Q92921251 | Hybrid Imaging of Aspergillus fumigatus Pulmonary Infection with Fluorescent, 68Ga-Labelled Siderophores |
| Q46679268 | Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. |
| Q39220175 | Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. |
| Q57794723 | Imaging of Pseudomonas aeruginosa infection with Ga-68 labelled pyoverdine for positron emission tomography |
| Q129353006 | Improved quality control of [177Lu]Lu-PSMA I&T |
| Q43164820 | Impurity in (68)Ga-peptide preparation using processed generator eluate. |
| Q36909826 | In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. |
| Q57757467 | In Vivo Characterization of 4 Ga-Labeled Multimeric RGD Peptides to Image αβ Integrin Expression in 2 Human Tumor Xenograft Mouse Models |
| Q40156559 | In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). |
| Q42563073 | In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging |
| Q36440766 | Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles |
| Q36373488 | Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue |
| Q33818847 | Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. |
| Q57757815 | Methodological considerations influence the clinical value of parathyroid localisation diagnostics |
| Q46980035 | Microbial challenge tests on nonradioactive TiO2-based 68Ge/68Ga generator columns |
| Q92153429 | Modifying the Siderophore Triacetylfusarinine C for Molecular Imaging of Fungal Infection |
| Q129352999 | Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors |
| Q58698193 | Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer |
| Q57757444 | Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression |
| Q57757864 | Myocardial fatty acid metabolism during acute cardiac allograft rejection |
| Q39689622 | Novel 99mTc '4 + 1' peptide conjugates: tuning the biodistribution by variation of coligands. |
| Q35676322 | Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates |
| Q92290250 | On-cartridge preparation and evaluation of 68Ga-, 89Zr- and 64Cu-precursors for cell radiolabelling |
| Q35589625 | Peptide targeted imaging of cancer. |
| Q59469661 | Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals |
| Q39512185 | Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. |
| Q36013562 | Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. |
| Q37103342 | Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients |
| Q40951810 | Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide |
| Q57757846 | Preparation,99mTc-Labeling, and in Vitro Characterization of Hynic and N3S Modified RC-160 and [TYR3]octreotide |
| Q57476685 | Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs |
| Q57757881 | Problems with fractionated cold kits |
| Q57757838 | Radiochemical purity of routinely prepared 99Tcm radiopharmaceuticals: A retrospective study |
| Q43253511 | Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals |
| Q51536300 | Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. |
| Q90977132 | Radionuclides: medicinal products or rather starting materials? |
| Q40518968 | Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis |
| Q51817347 | Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals. |
| Q39734320 | Radiopharmacy: regulations and legislations in relation to human applications |
| Q64055515 | Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89 |
| Q39944711 | Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours |
| Q36832801 | Selected ⁶⁸Ga-siderophores versus ⁶⁸Ga-colloid and ⁶⁸Ga-citrate: biodistribution and small animal imaging in mice |
| Q104619950 | Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates |
| Q104493851 | Siderophore Scaffold as Carrier for Antifungal Peptides in Therapy of Aspergillus fumigatus Infections |
| Q96114442 | Siderophore-Based Molecular Imaging of Fungal and Bacterial Infections-Current Status and Future Perspectives |
| Q37609134 | Siderophores for molecular imaging applications. |
| Q55098217 | Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. |
| Q48490662 | Small animal imaging using a conventional gamma camera exemplified in studies on the striatal dopaminergic system. |
| Q44206394 | Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease |
| Q57757820 | Surfactant protein B labelled with [99mTc(CO)3(H2O)3]+ retains biological activity in vitro |
| Q48590142 | Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors |
| Q38740239 | Targeting Gastrointestinal Stromal Tumor with 68Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines. |
| Q39529811 | Targeting properties of peptide-modified radiolabeled liposomal nanoparticles |
| Q57757887 | Technetium-99m human immunoglobulin scintigraphy in psoriatic arthropathy: first results |
| Q57757842 | Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence |
| Q53578187 | The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. |
| Q92575644 | The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397 |
| Q34755194 | The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides. |
| Q64226363 | The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented? |
| Q57757699 | The specific case of radiopharmaceuticals and GMP—activities of the Radiopharmacy Committee |
| Q57757868 | The use of electronic autoradiography in radiopharmacy |
| Q37390746 | Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles |
| Q90976678 | US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations |
| Q30827547 | Ultra-low activities of a common radioisotope for permission-free tracking of a drosophilid fly in its natural habitat |
| Q38342316 | Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach. |
| Q38933775 | [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation |
| Q31095114 | [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis |
| Q39559499 | [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. |
| Q40204297 | [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression |
| Q48923191 | [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study |
| Q57757898 | [Quality control of radiopharmaceuticals from the clinical aspect--a necessity?] |
| Q39252884 | [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison. |
| Q44209015 | ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma. |
Search more.